Mylan, Biocon enter deal on generic analog insulins

Deal focuses on generics of Lantus, Humalog, NovoLog

PITTSBURGH — Mylan and Biocon have a deal to develop and sell generic insulin-analog products for diabetes, Mylan said.

Under the deal, Mylan will have the rights to develop and market Biocon's Glargine, Lispro and Aspart, respectively generic versions of Sanofi's Lantus, Eli Lilly's Humalog and Novo Nordisk's NovoLog.

"This collaboration builds off our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products," Mylan CEO Heather Bresch said. "This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

Login or Register to post a comment.